<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T04:36:54Z</responseDate>
  <request identifier="oai:figshare.com:article/33716584" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33716584</identifier>
        <datestamp>2026-09-13T22:02:24Z</datestamp>
        <setSpec>category_13</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Supplementary file 1_A methodological framework for real-world performance studies of clinical variant classification platforms at early organizational stages.docx</dc:title>
          <dc:creator>Vladimir Mitev (24866263)</dc:creator>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>ACMG/AMP</dc:subject>
          <dc:subject>clinical bioinformatics</dc:subject>
          <dc:subject>inter-laboratory concordance</dc:subject>
          <dc:subject>methodological-disposition taxonomy</dc:subject>
          <dc:subject>multi-source ground truth</dc:subject>
          <dc:subject>rare disease genomics</dc:subject>
          <dc:subject>real-world performance</dc:subject>
          <dc:subject>variant classification</dc:subject>
          <dc:description>&lt;p&gt;Automated platforms that classify sequence variants under the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) framework are increasingly used in rare-disease genomics, yet methodology for characterizing their performance at an early organizational stage is underdeveloped. The two framings most common in the literature are poorly suited to this stage: single-source comparison treats one peer laboratory or curated set as ground truth, which is difficult to defend at evidence depths where qualified laboratories disagree 25%–35% of the time; and formal regulatory adjudication requires multi-adjudicator panels and quality-management infrastructure that small or single-founder developers do not yet have. This paper proposes a methodological framework for Real-World Performance Studies that occupies the space between informal in-house testing and formal regulatory adjudication. The framework has four components: a three-layer performance model that separates analytical, classification, and clinical performance and forces every observation to a locus of attribution; a multi-source ground-truth construction with an explicit, evidence-strength-ordered weighting hierarchy; a six-category methodological-disposition taxonomy that resolves platform-versus-comparator disagreement into characterized categories with distinct action implications, only one of which denotes a classifier defect; and a phased pathway that carries early-stage evidence forward toward eventual regulatory submission. The framework is demonstrated, not validated, on three real-world cohorts (97 scored cases across three classifier versions) of a variant classification platform developed by Helena Bioinformatics. The demonstration illustrates how the method is operationalized. It does not test, validate, or claim superiority for any system. The framework is non-proprietary and is offered for independent adoption and adaptation. Its principal limitations - single-platform demonstration, single peer comparator, a taxonomy developed on the same cohorts that illustrate it, and structurally challenging conflicts of interest - are stated explicitly and are the reason the paper claims a method, not a result. The proposed framework is a conceptual methodology operationalized as a structured human-in-the-loop protocol; it is not a turnkey software package, and empirical use requires version-locked automated outputs plus documented expert review.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-13T22:02:24Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fgene.2026.1925492.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Supplementary_file_1_A_methodological_framework_for_real-world_performance_studies_of_clinical_variant_classification_platforms_at_early_organizational_stages_docx/33716584</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
